Loading data for IOVA — first visit, this takes a few seconds.

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM: IOVA · 即時價格 · USD

8.17

+0.16 (2.00%)

收盤價： Sep 11, 2026, 4:31 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	3.76
市值	3.8B
營收 (ttm)	325M
淨利（ttm）	-290M
	0.83
	-0.69
	n/a
	-29.17
P/B (ttm)	5.16
P/S (ttm)	11.68
財報日期	Nov 5, 2026

賣價	4.98
成交量	12,118,090
20 日平均成交量	16,614,706
開盤價	7.95
前收盤價	8.01
當日區間	7.66 - 8.17
52 週範圍	1.76 - 9.36
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 IOVA

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresecta...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Oct 15, 2010

員工 975

證券交易所 NasdaqGM

股票代號 IOVA

網站 https://www.iovance.com

完整的公司簡介

財務表現

Iovance Biotherapeutics 在 2025 年的營收為 263.5M，較前一年的 164.07M 增加 60.6%。淨利為 -390.98M，較前期增加 5.05%。

財務報表

財報驚奇

Iovance Biotherapeutics 已於 Aug 6, 2026 公布季度財報：

營收為 $99.31M 低於預期 $0, 年增 65.65% 成長.
每股盈餘為 -0.11 超出預期 0.02, 年增 66.67% 成長.

下次財報發布

Iovance Biotherapeutics, Inc. 的下次財報預計於 Nov 5, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

2 週前 · Zacks

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

2 週前 · Zacks

5 Biotech Stocks Worth Adding to Your Portfolio Now

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

2 週前 · Simply Wall St.

Oracle Stock And 2 Growth Picks With Strong Earnings Potential

Germany’s Ifo index has reached a one year high, which hints at a more confident backdrop for companies planning to grow earnings rather than just defend margins. That creates an interesting setting f...